MISE AU POINT D’UN MODELE EXPERIMENTAL DE CANDIDOSE VAGINALE CHEZ LA SOURIS
Mots-clés :
Candidose vaginale, Candida albicans, souris, Benzoate d’oestradiolRésumé
On assiste à une recrudescence importante decas de mycoses superficielles, notamment les vulvovaginites candidosiques chez la femme. L’intérêt de la mise au point d’un modèle expérimental de la candidose vaginale s’est donc accrue ses dernières années pour étudier notamment, les différentes étapes de l’infestation de la muqueuse vaginale par les levures. Le modèle expérimental decandidose vaginale mis au point, est réalisé par inoculation intravaginale 25 µl d’une suspension de levures [2,5.106 UFC] chez la souris en oestrus permanent, entretenu par une injection hebdomadaire, en sous-cutané de 25 mg /kg de
Benzoate d’oestradiol.
Références
-ABU-ELTEEN KH. Increased incidence of vulvovaginal
candidiasis caused by Candida glabratain Jordan. Jpn. J. Infect. Dis., 54, (2001), pp. 103 – 107.
-BOHLER K., KLADE H., POITSCHEK C., and REINTHALLER A. Immunohistochemical study of in vivo and in vitroIgA coating of Candidaspecies in vulvovaginal candidiasis. Genitourinary Medecine, 70,[1994), pp. 182 – 186.
-BOHLER K., MEISINGER V., KLADE H., and REINTHALLER A. Zinc levels of serum and cervicovaginal secretion in recurrent vulvovaginal candidiasis. Genitourinary Medecine, 70, (1994), pp. 308 – 310.
-BUURMAN Ed.T., WESTWATER C., HUBE B., BROWN A.J.P., ODDS F.C., and GROW N.A.R. Molecular analysis of CaMnt1p, a mannosyl transferase important for adhesion and virulence of Candida albicans. Proc. Natl. Acad. Sci. USA: 95, [1998), pp. 7670 – 7675.
-CALDERONE R.A., LEHRER N. and SEGAL E. Adherence of Candida albicansto buccal and vaginal epithelial cells: ultrastructural observations. Can.J. Microbiol. 30 (1984), pp. 1001 – 1007.
-COTCH M.F., HILLIER S.L., GIBBS R.S., and ESCHENBACH D.A. Epidemiology and outcomes associated with moderate to heavy Candidacolonization during pregnancy. Vaginal infections and prematurity study group. Am. J. Obstet. Gynecol., 178(1998), pp. 374 – 380.
-De BERNARDIS F., CASSONEA., STURTEVANT J., and
CALDERONE R. Expression of Candida albicans SAP1 and
SAP2 in experimental vaginitis. Infect. Immun.,63, (1995), pp.
– 1892.
-DOUGLAS L.J. Adhesion of pathogenic species to host
surfaces. Microbiol. Sci., 2, (1985), pp. 243 – 247.
-FERRIS DG., HENDRICH J., PAYNE P.M., GETTS A., RASSEKH R., MATHIS D., and LITAKER M.S. Office laboratory diagnostic of vaginitis. Clinician-performed tests compared with a rapid nucleic acid hybridization test. J. Fam. Pract., 41(1995), pp. 575 – 81.
-FIDEL Jr.P.L., CUTRIGHT J., and STEELE C. Effect of reproductive hormones on experimental vaginal candidiasis.
Infect. Immun., 68 (2000), pp. 651 – 657.
-FIORILLO M., RIPEAU J.S., AUMONT F., BELHUMEUR P., et DE REPENTIGNY L. Expression in vivodes facteurs de virulence de Candida albicans. 68ème Congrès de l’Acfas 2000, Session : S-105 Microbiologie, Virologie.
-GALGIANI J.N. Susceptibility of Candida albicansand
other yeasts to fluconazole : Relation between in vitroand in
vivostudies. Rev. Infect. Dis., 12, (1990), pp. 272 – 275.
-GHELARDI E., TAVANITIA., LUPETTI A., CELANDRONI F., BOLDRINI E., CAMPA M. , and SENESI S. Control of Candida albicansmurine vaginitis by topical administration of polycarbophil-Econazole complex. Antimicrob. Agents and Chemoth., 42(1998), pp. 2434 – 2436.
- GIRALDO P., VON NOWASKONSKI A., GOMES F.A.,
LINHARES I., NEVES N.A., and WITKIN S.S. Vaginal colonization by Candida in asymptomatic women with and without a history of recurrent vulvovaginal candidiasis. Obstet. Gynecol., 95(2000), pp. 413 – 416.
- HAN Y., RICHARD P., MORRISON P., and CUTLER J.E.
A vaccine and monoclonal antibodies that enhance mouse
resistance to Candida albicansvaginal infection. Infect. Immun., 66(1998), pp. 5771 – 5776.
- HEERES I., and BACKX L.J.J. Antimycotic imidazoles.
Part 4 : Synthesis and antifungalactivity of Ketoconazole, a
new potent orally active broad spectrum antufungal agent. J. Med. Chem., 22, (1979), pp. 1003 – 1005.
- HIGASHIDE AMAN R. Clinical characteristics correlated
with different fungi causing vulvovaginal mycosis. Mycoses,
, (1988), pp. 213 – 226.
- KINSMAN O.S., and COLLARD A.E. Hormonal factors in
vaginal candidiasis in rats. Infect. Immun., 53, (1986), pp.
– 504.
- LEVINE H.B. Ketoconazole inthe management of fungal
disease. ADIS Press. Revised first edition. (1982)
- LEHRER N, SEGAL E., LIS H., and GOV Y. Effect of
Candida albicanscell wall componnents on the adhesion of the fungus to human and murine vaginal mucosa. Mycopathologia. 102, (1983), pp. 115-121.
- LEHRER N, SEGAL E., and BARR-NEA L. In vitroand in vivoadherence of Candida albicans to ucosal surfaces. Ann. Microbiol. (Paris)., 134B, (1983), pp. 293 – 306.
- LINAS M.D., et POURRUT J.C. Torulopsis glabrataau CHU RANGUEIL : Epidémiologie et pathogénie. Bull. Soc. MYCOL. Med., XV, (1986), pp. 135 – 138.
-MAROT-LEBLOND A., ROBERT R., LOISEAU O., APAIRE-MARCHAIS V. and SENET J.M. Hydrophobic and hydrophilic cell surface (glyco) proteinic components of Candida albicans. J. Myl. Méd., 10, (2000) pp.115 – 122.
- MARTINEZ A., FERRER S., SANTOS I., JIMENEZ E.,
SPARROWE J., REGADERA J. GOMEZ DE LAS HARAS F., and GARGALLO-VIOLA D. Antifungal activities of two new azasordarins, GW471552 and GW471558, in experimental models of oral and vulvovaginal candidiasis in immunosuppressed rats. Antimicrob. Agents. Chemoth., 45,
(2001), pp. 3304 – 3309.
- PELZER A. Vaginal mycoses during the menstruel cycle.
Mykosen. (1978), pp. 271 – 273.
- REDONDO-LOPEZ V., MERIWETHER C., SCHMITT C.,
OPTZ M., COOK R., and SOBEL J.D. Vulvovaginalcandidiasis complicating reccurent bacterial vaginosis. Sex. Transm. Dis. 17(1990), pp. 51 – 53.
- RIPEAU J.S., FIORILLO M., AUMONT F., BELHUMEUR P., et DE REPENTIGNY L. Expression des protéases aspartyles etde la phospholipase de Candida albicansau cours de l’infection in vivo.67ème Congrès de l’Acfas. (1999), Session : S-105 Biologie et génétique moléculaire.
-RYLEY J.F. Pathogenicity of Candida albicanswith particular reference to the vagina. J. Med. Vet. Mycol., 24, (1986), pp. 5 – 22.
-RYLEY J.F.,and McGREGOR S. Quantification of vaginal
Candida albicansinfections in rodents.J. Med. Vet. Mycol., 24, (1986), pp. 455 – 460.
-SAWYER S.M., BOWES G., and PHELAN P.D. Vulvovaginal candidiasis inyoung women with cystic fibrosis. B.M.J., , 308(1994), pp. 1609.
-SEGAL E., LEHRER N., and OFEK I. Adherence of candida albicans to human vaginal epithelial cells; inhibition by amino sugars. Exp. Cell. Biol., 50, (1982), pp. 13 – 17.
-SEGAL E., GOTTFRIED L., and LEHRER N. Candidal vaginitis in hormone treated mice: Prevention by a chitin extract. Mycopathologia, 102, (1988), pp. 157 – 163.
-SEGAL E., SOROKA A., and LEHRER N. Attachement of Candidato mammalian tissues : Clinical and experimental studies. Zentralbl. Bakteriol. Mickrobio. Hyg.(A). A257 (1984), pp. 257 – 265.
-SEGAL E., SOROKA A., and SCHECHTER A. Correlative
relationship between adherence of Candida albicansto human vaginal epithelial cells in vitroand candidal vaginitis. Sabouraudia. 22,(1984), pp.191– 200.
-SHIFRIN E., MATITYAHU D., FELDMAN J., and MINKOFF H. Determinants of incident vulvovaginal candidiasis in human immunodeficiency virus-positive women. Infect. Dis. Obstet. Gynecol., 8, (2000), pp. 176 – 180.
-SOBEL J.D., CHAIM W., and LEAMAN D. Recurrent
vulvovaginal candidiasis associated with long-term tamoxifen treatment in postmenopausal women. Obstet. Gynecol., 88, (1996), pp. 704 – 706.
- TASCHDJIAN C.L. and REISS F. Experimental vaginal
candidasis in mice: Its implications for superficial candidasis in humans. J. Invest. Derm., 34, (1960), pp. 89-94.
-THIENPONT D., and VAN CUTSEM J.Ketoconazole in experimental candidosis. Rev. Infect. Dis., 2, (1980), pp.
– 577.
-THIENPONT D., and VAN CUTSEM J. Ketoconazole a new broad spectrum orally active antimycotic. Experientia., 35, (1979), pp. 606 – 607.
-TROKE P.F., and ANDREWS R.J. Fluconazole and other azoles : translation of in vitroactivity to in vivo clinical afficacy. Rev. Infect. Dis., 12, (1990), pp. S276 – S280.
-TROKE P.F., and MARRIOTT M.S. In vitropotency and in
vivoactivity of azoles. Ann. N.Y. Acad. Sci., 544 (1988), pp.
– 293.
–YONGMOON H., MORRISON R.P., and CUTLER J.E. A
vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicansinfection. Infect. Immun., 66,
(1998), pp.5771 – 5776.
-UCHIDA K. Experimental candidiasis : participation of
indigenous bacterial flora and resistance factors of the host in
producing on animal mouse. Jpn., J. Med. Mycol., 29 (1988), pp. 169 – 181.
- VAN CAUTEREN H., and HEYKANTS J. Itraconazole: Pharmacologic studies in animals and humans. Rev. Infect. Dis., 9, (1987), pp. 43 – 46.
- VAN CUTSEM J., and VAN GERVEN. Activity of orally,
topically, and parenterally administered Itraconazole in the
treatment of superficial and deep mycoses : Animal model.
Rev. Infect. Diseases, 9, (1987), pp. 15 – 31.
- WATSON M.C., GRIMSHAW J.M., BOND C.M., MOLLISON J. and LUDBROOK A. Oral versus intravaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst. Rev., (2001), CD 002845.
